Learn All CategoriesAlzheimer’s disease(14)Article(4)Education(7)Epidermolysis Bullosa(1)events(2)Macular Degeneration(4)presentation(6)Uncategorised(15)Webinar(4) All TagsAlzheimer’s disease(4)Article(2) InMed Presents at Renmark Financial Virtual Non-Deal RoadshowMarch 10, 2026Read More InMed’s CEO Eric A. Adams Gives An Overview of Alzheimer’s Disease Drug Candidate INM-901February 23, 2026Read More Conference Presentation – InMed Presents at Life Sciences Forum December 11, 2025January 12, 2026Read More Fierce Biotech Article: Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease RiskOctober 27, 2025Read More InMed Presents at the 2025 Life Sciences Investor ForumOctober 14, 2025Read More InMed presents INM-901 data at 2025 Alzheimer’s Association International ConferenceAugust 18, 2025Read More Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next StepDecember 11, 2024Read More Article in Fierce Biotech: The Evolving Alzheimer’s Disease LandscapeAugust 26, 2024Read More What is Neuritogenesis? How does Neuritogenesis Affect Alzheimer’s Disease?August 16, 2024Read More Article: InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular DegenerationJuly 25, 2024Read More InMed’s INM-901 for Alzheimer’s Disease – Preclinical Data SummaryJuly 25, 2024Read More Article: InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s DiseaseJuly 22, 2024Read More 123123 Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
